Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations

被引:12
作者
Qin, Qi [1 ,4 ]
Wei, Cuibai [1 ]
Piao, YueShan [2 ]
Lian, Fang [2 ]
Wu, Hao [3 ]
Zhou, Aihong [1 ]
Wang, Fen [1 ]
Zuo, Xiumei [1 ]
Han, Yue [1 ]
Lyu, Jihui [3 ]
Guo, Dongmei [1 ]
Jia, Jianping [1 ,5 ,6 ,7 ]
机构
[1] Capital Med Univ, Dept Neurol, Innovat Ctr Neurol Disorders, Xuanwu Hosp, 45 Changchun St, Beijing 100053, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Dept Pathol, Beijing, Peoples R China
[3] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China
[4] Beijing Geriatr Hosp, Ctr Cognit Disorders, Beijing, Peoples R China
[5] Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Beijing, Peoples R China
[6] Beijing Key Lab Geriatr Cognit Disorders, Beijing, Peoples R China
[7] Neurodegenerat Lab Minist Educ Peoples Republ, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
leptomeningeal amyloidosis; transthyretin; leptomeningeal enhancement; TTR mutations; FAMILIAL OCULOLEPTOMENINGEAL AMYLOIDOSIS; LIVER-TRANSPLANTATION; VARIANT; POLYNEUROPATHY; DIFLUNISAL; DIAGNOSIS; THERAPY; RARE; TAFAMIDIS; EFFICACY;
D O I
10.1097/NRL.0000000000000337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Leptomeningeal amyloidosis (LA) represents a rare subtype of familial transthyretin (TTR) amyloidosis, characterized by deposition of amyloid in cranial and spinal leptomeninges. Of >120 TTR mutations identified, few have been associated with LA. Case Report: A 27-year-old male presented with a 2-year history of progressive symptoms including cognitive decline and right-sided weakness and numbness. Cerebrospinal fluid (CSF) analyses demonstrated high protein level. Gadolinium-enhanced magnetic resonance imaging (MRI) revealed extensive leptomeningeal enhancement over the surface of the brain and spinal cord. Pathologic analyses revealed a TTR mutation c.113A>G (p.D38G). Review Summary: Fifteen mutations and genotype-phenotype correlation of 72 LA patients have been summarized to provide an overview of LA associated with transthyretin mutations. The mean age of clinical onset was 44.9 years and the neurological symptoms primarily included cognitive impairment, headache, ataxia seizures and hearing, visual loss. CSF analysis showed elevated high CSF protein level and MRI revealed extensive leptomeningeal enhancement. Conclusion: Clinicians should be aware of this rare form of familial transthyretin amyloidosis as well as its typical MRI enhancement and high CSF protein. The important role of biopsy, genetic testing and the potential early diagnosis value of contrast MRI were suggested. Early recognition of these characteristics is important to provide misdiagnosis and shorten the time before correct diagnosis. These findings expand the phenotypic spectrum of TTR gene and have implications for the diagnosis, treatment, and systematic study of LA.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [41] Transthyretin cardiac amyloidosis
    Porcari, Aldostefano
    Fontana, Marianna
    Gillmore, Julian D.
    CARDIOVASCULAR RESEARCH, 2023, 118 (18) : 3517 - 3535
  • [42] Hereditary transthyretin amyloidosis
    Hund, E.
    NERVENARZT, 2014, 85 (10): : 1291 - 1297
  • [43] Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
    Tschoepe, Carsten
    Elsanhoury, Ahmed
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [44] Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis
    Gawor, Monika
    Holcman, Katarzyna
    Franaszczyk, Maria
    Lipowska, Marta
    Michalek, Piotr
    Teresinska, Anna
    Bilinska, Zofia T.
    Rubis, Pawel
    Kostkiewicz, Magdalena
    Szot, Wojciech
    Podolec, Piotr
    Grzybowski, Jacek
    CARDIOLOGY JOURNAL, 2020, : 985 - 993
  • [45] Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis
    Plumadore, Emily
    Lombardo, Lindsay
    Cabral, Katherine P.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (02) : 52 - 62
  • [46] Transthyretin cardiac amyloidosis: an update on diagnosis and treatment
    Yamamoto, Hiroyuki
    Yokochi, Tomoki
    ESC HEART FAILURE, 2019, 6 (06): : 1128 - 1139
  • [47] Recent progress in the understanding and treatment of transthyretin amyloidosis
    Sekijima, Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (03) : 225 - 233
  • [48] DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis
    Akinboboye, Ola
    Shah, Keyur
    Warner, Alberta L.
    Damy, Thibaud
    Taylor, Herman A.
    Gollob, Jared
    Powell, Christine
    Karsten, Verena
    Vest, John
    Maurer, Mathew S.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (04): : 223 - 230
  • [49] The use of diflunisal for transthyretin cardiac amyloidosis: a review
    Ibrahim, Michel
    Saint Croix, Garly Rushler
    Lacy, Spencer
    Fattouh, Michael
    Barillas-Lara, Maria Irene
    Behrooz, Leili
    Mechanic, Olivia
    HEART FAILURE REVIEWS, 2022, 27 (02) : 517 - 524
  • [50] Comparison of patients with mutations associated with hereditary transthyretin amyloidosis and other neuromuscular diseases
    Khella, Sami
    Desai, Urvi
    Towne, Meghan
    Narayana, Arvind
    Olugemo, Kemi
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 392 - 392